This trial is an open-label extension of the double-blind study, which means that all participants will receive pimavanserin for an additional 52 weeks. The purpose of this trial is to determine the long-term safety and tolerability of pimavanserin in this population.
1 Primary · 1 Secondary · Reporting Duration: 52 weeks
Experimental Treatment
228 Total Participants · 1 Treatment Group
Primary Treatment: Pimavanserin · No Placebo Group · Phase 2 & 3
Age 5 - 18 · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: